Associated Papers
Ligand-specific pharmacogenetic effects of nonsynonymous mutations.
Morningstar-Kywi N et al.
Pharmacogenetics and Genomics, 2021
Influence of DRD2 Polymorphisms on the Clinical Outcomes of Opioiddependent Patients on Methadone Maintenance Therapy.
Zahari Z et al.
Journal of Pharmacy & Bioallied Sciences, 2020
Genetic variants in dopamine receptors influence on heterodimerization in the context of antipsychotic drug action.
Faron-Górecka A et al.
Progress in Molecular Biology and Translational Science, 2020
Genetic variants of dopamine D2 receptor impact heterodimerization with dopamine D1 receptor.
Błasiak E et al.
Pharmacological Reports : Pr, 2017
Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.
Ma Y et al.
Molecular Neurobiology, 2015
Tridimensional personalities and polymorphism of dopamine D2 receptor among heroin addicts.
Teh LK et al.
Biological Research for Nursing, 2012
A Nested Allele-Specific Multiplex Polymerase Chain Reaction Method for the Detection of DRD2 Polymorphisms.
Zahari Z et al.
The Malaysian Journal of Medical Sciences : Mjms, 2011
Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.
Lafuente A et al.
Psychiatry Research, 2008
Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population.
Vijayan NN et al.
Behavioral and Brain Functions : Bbf, 2007
Gene-environment interactions in sporadic Parkinson's disease.
Benmoyal-Segal L et al.
Journal of Neurochemistry, 2006
Pharmacogenetics as a tool in the therapy of schizophrenia.
Wilffert B et al.
Pharmacy World & Science : Pws, 2005
Analysis of transmission of novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene in patients with autism.
Lauritsen MB et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics, 2003
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
Kaiser R et al.
Neurology, 2003
Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor.
Duan J et al.
Human Molecular Genetics, 2003
Association between smoking habits and dopamine receptor D2 taqI A A2 allele in Japanese males: a confirmatory study.
Hamajima N et al.
Journal of Epidemiology, 2002
Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
Kaiser R et al.
Molecular Psychiatry, 2002
A Ser311Cys mutation in the human dopamine receptor D2 gene is associated with reduced energy expenditure.
Tataranni PA et al.
Diabetes, 2001
Functional variant in the DRD2 receptor promoter region and subtypes of alcoholism.
Parsian A et al.
American Journal of Medical Genetics, 2000
Association between a polymorphism in the promoter region of the dopamine D2 receptor gene and schizophrenia in Japanese subjects: replication and evaluation for antipsychotic-related features.
Inada T et al.
The International Journal of Neuropsychopharmacology, 1999
Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants.
Cravchik A et al.
Pharmacogenetics, 1999
Insertion/deletion variant (-141C Ins/Del) in the 5' regulatory region of the dopamine D2 receptor gene: lack of association with schizophrenia and bipolar affective disorder. Short communication.
Stöber G et al.
Journal of Neural Transmission (vienna, Austria : 1996), 1998
Linkage and association of a functional DRD2 variant [Ser311Cys] and DRD2 markers to alcoholism, substance abuse and schizophrenia in Southwestern American Indians.
Goldman D et al.
American Journal of Medical Genetics, 1997
Detection of altered methylation of MB-COMT promotor and DRD2 gene in cannabinoid or synthetic cannabinoid use disorder regarding gene variants and clinical parameters.
Oyaci Y et al.
Journal of Addictive Diseases, 0